Search
Close this search box.
Search
Close this search box.

January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan.

Vision becomes reality with willpower and knowledge

Our guest today, Tsgerieda Gebrehiwet, is a passionate painter and pharmacist. As a student, in addition to her education, she spent a lot of her time helping out in her family’s business.• Would you please introduce yourself to our readers?I was born …

Can Berlin and Paris reset ‘strained’ EU-Ethiopia ties?

Germany and France have dispatched their top envoys to Ethiopia to revamp relations strained by the Tigray conflict. Analysts say the EU member states are keen to support the reconstruction process but challenges remain.German Foreign Minister Annalena…